|
業務類別
|
Biotechnology |
|
業務概覽
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom. |
| 公司地址
| Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS |
| 電話號碼
| +44 1223261503 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bicycletherapeutics.com |
| 員工數量
| 288 |
| Dr. Kevin Lee, M.B.A.,PhD |
Director and Chief Executive Officer |
美元 862.34K |
22/04/2026 |
| Dr. Michael Skynner, PhD |
Chief Scientific Officer |
美元 612.47K |
22/04/2026 |
| Mr. Alistair Milnes |
Chief Corporate Development Officer |
美元 578.19K |
17/03/2026 |
| Mr. Travis Thompson |
Chief Financial Officer |
-- |
03/02/2026 |
| Dr. Michael Charles Ferguson Hannay, D.Sc. |
Chief Product and Supply Chain Officer |
-- |
22/04/2026 |
| Dr. Jennifer Perry, Pharm.D. |
Chief Operating Officer |
-- |
17/03/2026 |
|
|
| Dr. Felix J. Baker, PhD |
Chairman of the Board |
22/04/2026 |
| Mr. Herve Hoppenot |
Independent Director |
22/04/2026 |
| Dr. Jose-Carlos Gutierrez-Ramos, PhD |
Independent Director |
22/04/2026 |
| Dr. Roger D. Dansey, M.D. |
Independent Director |
22/04/2026 |
| Dr. Kevin Lee, M.B.A.,PhD |
Director and Chief Executive Officer |
22/04/2026 |
| Dr. Charles Swanton, M.D.,PhD |
Director |
22/04/2026 |
| Dr. Alessandro Riva, M.D. |
Independent Director |
22/04/2026 |
| Mr. Stephen Sands |
Independent Director |
22/04/2026 |
|
|
|
|
